Clinical Trial

Evaluation of NWRD09 for HPV-16 Related Cervical HSIL

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD09 administered by intramuscular (IM) injection in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) associated with human papillomavirus (HPV) 16.
Trial Details
NCT Number NCT07712692
Lead Sponsor Newish Biotech (Wuxi) Co., Ltd.
Conditions High-grade Squamous Intraepithelial Lesion (HSIL)
Enrollment 156 participants
Start Date 2026-08-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-17